Bristol-Myers Squibb Co.’s chief medical officer is stepping down from his role after six years at the company, a surprise ...

BMY rises 6.3% in a month as investors pin hopes on new drugs to offset pressure from pipeline and patent losses.

The company’s AI approach allows molecule candidates to be vetted for efficacy and other properties early in development.

Bristol Myers Squibb said on Friday its blockbuster drug Reblozyl in combination with another therapy failed to meet the main ...

Bristol Myers Squibb appoints Cristian Massacesi as EVP, Chief Medical Officer, & Head of Development starting Aug 2025.

Bristol Myers Squibb's chief medical officer, Samit Hirawat, is leaving the drugmaker to pursue new professional opportunities.

Bristol Myers Squibb has raided AstraZeneca to find its next chief medical officer (CMO), persuading Cristian Massacesi, M.D.

Bristol Myers Squibb has appointed Cristian Massacesi, M.D., as Executive Vice President, Chief Medical Officer, and Head of Development.

IL-17 inhibitors are approved for axial spondyloarthritis and psoriatic arthritis, but their effectiveness in heavily ...

Bristol Myers Squibb has appointed Dr Cristian Massacesi as Executive Vice President, Chief Medical Officer and Head of ...

The FDA has accepted for review the sNDA for deucravacitinib for the treatment of adults with active psoriatic arthritis.

In recently reported case studies, nemolizumab, approved for two indications associated with itch, has been reported to be ...